TerrAscend Corp. TER TRSSF announced Monday that it has finalized a non-brokered private placement with orders reaching a total of around $33.5 million, including the first tranche of the private placement that was completed Dec. 30.
Company chairman Jason Wild, executive chairman Jason Ackerman and each of the directors were engaged in the private placement, according to TerrAscend.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
For the Jan. 10 closing of the second tranche of the private placement, TerrAscend said it issued 3.45 million units with a price of CA$2.45 ($1.88) each for proceeds of CA$8.45 million.
Each unit consists of one company share and one common share purchase warrant, with each warrant usable to purchase one common share before Jan. 14, 2022 at a price of CA$3.25 per warrant share.
TerrAscend said it plans to utilize the proceeds to push for the finalization of its New Jersey cultivation and processing facilities and to complete a January 2020 purchase price payment in relation to the purchase of Ilera Healthcare.
TerrAscend’s shares closed Friday’s market session 13.04% higher at $2.10 per share.
Related Links:
TerrAscend Trades Down After Announcing Q3 Results
Cannabis 2.0: The Companies Entering Canada's New Edible, Concentrate, Topical Market
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
